-transparent.png){kind=logo}
Three inhalation formulations of ICI 204,219 were compared for antagonism of antigen-induced bronchoconstriction in 16 subjects with asthma who demonstrated reproducible hypersensitivity to allergen during screening challenges. Each subject received a single 0.2-mg dose of each formulation and was challenged with ragweed 30 min after administration of ICI 204,219 until the forced expiratory volume in 1 s (FEV1) decreased by 20 percent or the maximum allergen concentration (100 micrograms/ml) was reached. The majority of subjects tolerated 100 micrograms/ml of allergen without a 20 percent decrease in FEV1. Inhalation formulations of ICI 204,219 successfully inhibited bronchoconstriction in subjects with reproducible sensitivity to ragweed challenges.
R A Nathan, and
M Glass, and
M C Minkwitz
May 1992,
The Journal of allergy and clinical immunology,
R A Nathan, and
M Glass, and
M C Minkwitz
October 1993,
Clinical pharmacology and therapeutics,
R A Nathan, and
M Glass, and
M C Minkwitz
April 1990,
The American review of respiratory disease,
R A Nathan, and
M Glass, and
M C Minkwitz
June 1993,
The American review of respiratory disease,
R A Nathan, and
M Glass, and
M C Minkwitz
August 1996,
American journal of respiratory and critical care medicine,
R A Nathan, and
M Glass, and
M C Minkwitz
January 1991,
Advances in prostaglandin, thromboxane, and leukotriene research,
R A Nathan, and
M Glass, and
M C Minkwitz
January 1993,
The American review of respiratory disease,
R A Nathan, and
M Glass, and
M C Minkwitz
September 1994,
American journal of respiratory and critical care medicine,
R A Nathan, and
M Glass, and
M C Minkwitz
July 1991,
Chest,
R A Nathan, and
M Glass, and
M C Minkwitz
July 1993,
The New England journal of medicine,
